Nurix therapeutics appoints leading industry strategist edward c. saltzman to its board of directors

San francisco, sept. 14, 2022 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of edward c. saltzman to its board of directors. mr. saltzman has over 30 years of drug strategic development experience in the biopharmaceutical and biotechnology industries, and currently serves as head of biotech strategy at lumanity inc., a global pharmaceutical and biotechnology advisory firm.
NRIX Ratings Summary
NRIX Quant Ranking